Regeneus Ltd. (AU:CMB)
ASX:CMB
Want to see AU:CMB full AI Analyst Report?
CMB Stock Chart & Stats
AU$0.47
-AU$0.02(-4.44%)
At close: 4:00 PM EST
AU$0.47
-AU$0.02(-4.44%)
Day’s Range― - ―
52-Week RangeAU$0.19 - AU$0.60
Previous CloseN/A
Volume21.69K
Average Volume (3M)3.93K
Market Cap
AU$12.03M
Enterprise ValueAU$10.88M
Total Cash (Recent Filing)AU$166.41K
Total Debt (Recent Filing)AU$482.71K
Price to Earnings (P/E)―
Beta-4.37
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding27,331,919
10 Day Avg. Volume7,693
30 Day Avg. Volume3,926
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.09
Price to Sales (P/S)5.73
P/FCF Ratio-0.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Recovery & Gross MarginA sharp revenue rebound alongside a ~69% gross margin signals improving commercial traction and attractive unit economics. Over the next 2-6 months, sustained margin at higher volumes can meaningfully improve operating leverage and the pathway to narrowing losses if top-line growth continues.
Moderate LeverageRelatively low financial leverage reduces interest burden and preserves balance sheet flexibility. This structural cushion helps the company fund R&D and manufacturing needs near term without heavy debt servicing, lowering the immediacy of solvency pressure compared with highly indebted peers.
Proprietary Products And Manufacturing/IPOwning cell-therapy IP and in-house manufacturing creates durable barriers to entry and control over product quality and scale-up. For a regenerative-medicine company, this structural capability supports commercialisation, partnership value and long-term competitive differentiation if clinical outcomes and regulatory approvals progress.
Bears Say
High Cash Burn / Negative FCFMaterial negative operating and free cash flow indicate significant ongoing cash burn that will compress runway absent new capital or cost reductions. Structurally, persistent outflows constrain the company’s ability to fund trials, scale commercial operations and invest in manufacturing without dilutive financing.
Ongoing Net LossesSustained net losses and wide operating deficits show the current revenue base cannot cover fixed and operating costs. Without durable revenue scale or materially lower costs, profitability remains distant, raising continual funding needs and impairing return-on-capital prospects for investors and partners.
Balance Sheet Stress And Prior Negative EquityA history of negative equity and a material decline in shareholders' equity increase solvency and dilution risk. Structurally, this makes future capital raises more dilutive or expensive, can limit strategic options, and weakens stakeholder confidence over the medium term.
Regeneus Ltd. News
CMB FAQ
What was Regeneus Ltd.’s price range in the past 12 months?
Regeneus Ltd. lowest share price was AU$0.19 and its highest was AU$0.60 in the past 12 months.
What is Regeneus Ltd.’s market cap?
Regeneus Ltd.’s market cap is AU$12.03M.
When is Regeneus Ltd.’s upcoming earnings report date?
Regeneus Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 132 days.
How were Regeneus Ltd.’s earnings last quarter?
Regeneus Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.07 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.07.
Is Regeneus Ltd. overvalued?
According to Wall Street analysts Regeneus Ltd.’s price is currently Overvalued.
Does Regeneus Ltd. pay dividends?
Regeneus Ltd. does not currently pay dividends.
What is Regeneus Ltd.’s EPS estimate?
Regeneus Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Regeneus Ltd. have?
Regeneus Ltd. has 27,331,919 shares outstanding.
What happened to Regeneus Ltd.’s price movement after its last earnings report?
Regeneus Ltd. reported an EPS of -AU$0.07 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Regeneus Ltd.?
Currently, no hedge funds are holding shares in AU:CMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Regeneus Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.22%
12-Months-Change
Fundamentals
Return on Equity
-218.76%
Trailing 12-Months
Asset Growth
-5.07%
Trailing 12-Months
Company Description
Regeneus Ltd.
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Technical Analysis
Zelira Therapeutics
―
Invex Therapeutics Ltd.
―
AdAlta Ltd.
―
Bio-Gene Technology Ltd.
―
Hexima Ltd
―
Options Prices
Currently, No data available
---